Replimune Group Stock Price To Sales
| REPL Stock | USD 14.08 0.03 0.21% |
Replimune Group fundamentals help investors to digest information that contributes to Replimune's financial success or failures. It also enables traders to predict the movement of Replimune Stock. The fundamental analysis module provides a way to measure Replimune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Replimune stock.
| Last Reported | Projected for Next Year |
Replimune | Price To Sales |
Replimune Group Company Price To Sales Analysis
Replimune's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Replimune Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Replimune is extremely important. It helps to project a fair market value of Replimune Stock properly, considering its historical fundamentals such as Price To Sales. Since Replimune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Replimune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Replimune's interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Replimune Group has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Replimune Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Replimune's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Replimune could also be used in its relative valuation, which is a method of valuing Replimune by comparing valuation metrics of similar companies.Replimune is currently under evaluation in price to sales category among its peers.
Replimune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Replimune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Replimune's managers, analysts, and investors.Environmental | Governance | Social |
Replimune Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 727.6 M | ||||
| Shares Outstanding | 76.96 M | ||||
| Shares Owned By Insiders | 4.19 % | ||||
| Shares Owned By Institutions | 92.10 % | ||||
| Number Of Shares Shorted | 6.68 M | ||||
| Price To Book | 2.84 X | ||||
| EBITDA | (230.2 M) | ||||
| Net Income | (215.79 M) | ||||
| Cash And Equivalents | 395.08 M | ||||
| Cash Per Share | 8.01 X | ||||
| Total Debt | 75.87 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 19.79 X | ||||
| Book Value Per Share | 5.58 X | ||||
| Cash Flow From Operations | (185.47 M) | ||||
| Short Ratio | 15.19 X | ||||
| Earnings Per Share | (3.04) X | ||||
| Target Price | 16.5 | ||||
| Number Of Employees | 331 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 1.08 B | ||||
| Total Asset | 487.72 M | ||||
| Retained Earnings | (701.28 M) | ||||
| Working Capital | 393.23 M | ||||
| Net Asset | 487.72 M |
About Replimune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Replimune Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Replimune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Replimune Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Replimune Piotroski F Score and Replimune Altman Z Score analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.